ALT vs. PHAT, ATXS, KRRO, AVBP, CALT, PAHC, STOK, OLMA, ANAB, and CMPS
Should you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include Phathom Pharmaceuticals (PHAT), Astria Therapeutics (ATXS), Korro Bio (KRRO), ArriVent BioPharma (AVBP), Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Stoke Therapeutics (STOK), Olema Pharmaceuticals (OLMA), AnaptysBio (ANAB), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical preparations" industry.
Phathom Pharmaceuticals (NASDAQ:PHAT) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.
Phathom Pharmaceuticals presently has a consensus target price of $21.33, indicating a potential upside of 134.43%. Altimmune has a consensus target price of $15.00, indicating a potential upside of 108.33%. Given Altimmune's stronger consensus rating and higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Altimmune.
Phathom Pharmaceuticals received 16 more outperform votes than Altimmune when rated by MarketBeat users. However, 70.15% of users gave Altimmune an outperform vote while only 65.63% of users gave Phathom Pharmaceuticals an outperform vote.
Altimmune has lower revenue, but higher earnings than Phathom Pharmaceuticals. Altimmune is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Phathom Pharmaceuticals had 1 more articles in the media than Altimmune. MarketBeat recorded 8 mentions for Phathom Pharmaceuticals and 7 mentions for Altimmune. Phathom Pharmaceuticals' average media sentiment score of 0.80 beat Altimmune's score of 0.11 indicating that Altimmune is being referred to more favorably in the news media.
99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 24.1% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 4.1% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Phathom Pharmaceuticals has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500.
Phathom Pharmaceuticals has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -20,780.75%. Altimmune's return on equity of 0.00% beat Phathom Pharmaceuticals' return on equity.
Summary
Phathom Pharmaceuticals beats Altimmune on 12 of the 18 factors compared between the two stocks.
Get Altimmune News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Altimmune Competitors List
Related Companies and Tools
